Evidence‑Based Guidelines for Spinal Meningioma Diagnosis and Management

Diagnostic Imaging

Contrast‑enhanced MRI is the mandatory gold‑standard imaging modality and should be performed promptly when spinal meningioma is suspected. This recommendation applies to all patients with clinical suspicion, regardless of age or symptom duration. 1
Key MRI features include a dural‑based enhancing mass with a possible “dural tail” sign, cortical buckling, and a CSF cleft separating the tumor from the spinal cord. Recognition of these characteristics aids accurate diagnosis and surgical planning. 1, 2
CT scanning is advised to detect calcifications (up to 50 % of lesions) and to evaluate bony involvement, especially in ossified meningiomas. This adjunct imaging helps anticipate technical challenges during resection. 2
In pediatric patients requiring general anesthesia for brain MRI, a concurrent spinal MRI should be obtained to screen for additional spinal lesions. This approach minimizes the need for separate anesthetic exposures. 1
For very large tumors, pre‑operative angiography with possible embolization is recommended to reduce intra‑operative blood loss. Embolization should be considered when vascularity is high and surgical bleeding risk is a concern. 1

High‑dose dexamethasone should be initiated immediately in patients presenting with progressive neurological deficits to reduce peritumoral edema. Early steroid therapy can stabilize neurological function while definitive treatment is arranged. 1

Complete surgical resection, including removal of the dural attachment, is the treatment of choice for all symptomatic spinal meningiomas. The goal is gross‑total removal whenever feasible, balancing tumor clearance with preservation of neurological function. 1

Incidentally discovered small, asymptomatic spinal meningiomas may be managed conservatively with serial contrast‑enhanced MRI every 6–12 months. Observation is appropriate when the lesion is radiologically stable and the patient lacks neurological impairment. 3

Clinical Scenario	Recommended Imaging	Management Decision
Suspected spinal meningioma	Immediate contrast‑enhanced MRI	Proceed to definitive treatment planning
Need to assess calcification or bone involvement	CT scan	Adjust surgical approach if ossification present
Pediatric patient undergoing brain MRI	Add spinal MRI in same session	Detect concurrent spinal lesions without extra anesthesia
Large, highly vascular tumor	Pre‑operative angiography ± embolization	Reduce intra‑operative blood loss before resection
Small, asymptomatic lesion	Serial MRI (6–12 mo)	Continue observation unless growth or symptoms develop

All recommendations are derived from peer‑reviewed evidence cited above.

Incomplete resection of benign (WHO grade I) spinal meningioma: Post‑operative external‑beam radiotherapy delivering ≥ 50 Gy improves local control and 10‑year progression‑free survival from < 40 % to ≈ 70 %【4】.
WHO grade II (atypical) meningioma with subtotal resection: External‑beam radiotherapy of 45–54 Gy is recommended irrespective of the extent of resection【5】【4】.
WHO grade III (anaplastic/malignant) meningioma: Post‑operative radiotherapy of 45–54 Gy is advised regardless of resection status【5】【4】.
Gross‑total resection of WHO grade I meningioma: A watch‑and‑wait strategy with MRI surveillance every 6–12 months is advised; up to 20 % may recur within 25 years【4】.

Standard regimen for spinal meningioma: 50–55 Gy delivered in conventional fractions of 1.8–2.0 Gy per session【6】【7】.
Dose escalation to 60 Gy: Considered only in exceptional circumstances such as WHO grade III disease【6】【7】.
Treatment schedule: All fields are treated daily, five days per week【6】【7】.
Dose‑response relationship: A total dose ≥ 53 Gy raises 5‑year progression‑free survival from 17 % to 63 % in incompletely resected malignant meningiomas【5】【8】.

Gross Tumor Volume (GTV): Defined as macroscopic disease and the prior tumor bed on pre‑ and post‑operative contrast‑enhanced T1‑weighted MRI【6】【7】.
Planning Target Volume (PTV) margins: 0.5–1.0 cm expansion for benign and atypical lesions; 1.0–1.5 cm for anaplastic lesions【6】【7】.
Inclusion of dural tail and abnormal bone: Radiotherapy fields should generally encompass the dural tail and any radiologically abnormal bone【6】【7】.

SRS for small lesions (< 3–3.5 cm): Provides > 90 % 5‑year tumor‑control rates for benign meningiomas in difficult surgical locations (e.g., skull‑base sites)【5】【8】.
Hypofractionated Stereotactic Radiotherapy (HSRT): Delivered in ≤ 5 fractions with ≥ 5 Gy per fraction, offering a middle ground between single‑fraction SRS and conventional fractionation【9】.

Avoid routine irradiation of completely resected WHO grade I lesions: Observation is appropriate after gross‑total resection【4】.
Do not use doses < 50 Gy for incompletely resected lesions: Lower doses, especially < 53 Gy, are linked to inferior local control【5】【4】.
Prompt radiotherapy for WHO grade III lesions: Delaying adjuvant treatment is discouraged; immediate postoperative radiotherapy is required【5】【4】.

Annual MRI for at least 10 years: Recommended because late recurrences can occur, with some benign meningiomas recurring up to 25 years after initial treatment【6】【7】.